Zentalis Pharmaceuticals has priced an underwritten public offering of 23 million shares of common stock at $3.50 per share, with gross proceeds expected to reach approximately $80.5 million.
The offering is expected to close on August 17, 2026, subject to customary conditions. Underwriters also have a 30-day option to purchase up to an additional 3.45 million shares.
Also read: WHO Secures $3 Million to Strengthen Community-Led Response to Bundibugyo Virus Disease
The company plans to use the net proceeds, together with existing cash and securities, to support clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic development, and pre-commercial activities.
The funding will support the development of azenosertib, an investigational WEE1 inhibitor being studied as a potential targeted treatment for ovarian cancer and other tumor types.
